The use of the Hemochron activated clotting time (ACT) for determining adequacy of reversal of heparin following cardiopulmonary bypass was evaluated in 20 patients and compared with standard laboratory tests of coagulation. The commonly used Celite ACT method proved too insensitive to have any useful predictive value in detecting or quantifying residual heparin and removal of the Celite activation rendered the test even less sensitive. In contrast, the partial thromboplastin time with kaolin (PTTK) proved to correlate well with residual heparin (r = 0.79). It is, therefore, recommended that the use of the Hemochron following protamine administration be abandoned in favour of the PTTK.
Get full access to this article
View all access options for this article.
References
1.
Ellison NE, Ominski AJ, Wollman M.Is protamine a clinically important anticoagulant? A negative answer. Anaesthesiology1971; 35: 621-29.
2.
Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H., Spencer FCThe role of the activated clotting time in heparin administration and neutralisation for cardiopulmonary bypass. J Thorac Cardiovasc Surg1982; 85: 174-85.
3.
Miller WM, Binford JM, Hessell EAResults of a survey of the professional activities of 811 cardiopulmonary perfusionists. J Thorac Cardiovasc Surg1982 ; 83: 385-89.
4.
Berger RLReduced protamine dosage for heparin neutralisation in open heart operations . Circulation1967; 38 (Suppl. 2): 154-57.
5.
Babka R., Colby C., El-Etr A., Pifarre R.Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass. J Thorac Cardiovasc Surg1974; 73: 780-82.
6.
Bull BS, Huse WM, Brauer FS, Korpman RAHeparin therapy during extracorporeal circulation. II. The use of dose-response curves to individualise the heparin and protamine dose. J Thorac Cardiovasc Surg1975; 69: 685-89.
7.
Hemochron System. Instruction and technical guide. International Technidyne Corporation. September, 1983.
Teien AN, Lie M.Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res1977; 10: 399.
10.
Ellison NG, Beatty CP, Blake DR, Wurzel HA, MacVaugh H.Heparin rebound in patients and volunteers. J Thorac Cardiovasc Surg1974; 67: 723-29.
11.
Anderson MN , Mendelow N., Alfano GWExperimental studies of heparin-protamine activity with special reference to protamine inhibition of clotting. Surgery1959; 46: 1060-68.
12.
Ellison N., Edmunds LH, Colman RWPlatelet aggregation following heparin and protamine administration. Anaesthesiology1978; 48: 65-69.
13.
Bull BS, Korpman RA, Huse WM, Briggs BDHeparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg1974; 67: 723-29.
14.
Hattersley PGActivated clotting time of whole blood. JAMA1966; 196: 150-54.
15.
Culliford AT , Gitel SN, Starr N. et al. Lack of correlation between the plasma heparin level and the ACT during cardiopulmonary bypass. Ann Surg1981; 193: 105-11.
